Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.
The results of this controlled study of the treatment of 57 patients with Gilles de la Tourette's syndrome suggested that both haloperidol and pimozide were more effective than placebo, but that haloperidol was slightly more effective than pimozide. Adverse effects occurred more frequently with haloperidol vs placebo than with pimozide vs placebo, but the frequency was not significantly different for haloperidol compared with pimozide. Clinically significant cardiac effects did not occur at a maximum dosage of 0.3 mg/kg or 20 mg/d for pimozide and 10 mg/d for haloperidol. However, the QTc interval was prolonged during pimozide treatment compared with that during haloperidol treatment, although the values for both medications were not in an abnormal range.
Shapiro
E
E
Tourette and Tic Laboratory and Clinic, New York, NY 10028.
Shapiro
A K
AK
Fulop
G
G
Hubbard
M
M
Mandeli
J
J
Nordlie
J
J
Phillips
R A
RA
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D010868:Pimozide / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D012189:Retrospective Studies; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000523:psychology
D010919:Placebos; D010868:Pimozide; D006220:Haloperidol